The EMA’s Head of Advanced Therapies Dr Ana Hidalgo-Simon outlines Europe’s evolving regulatory framework for regenerative medicines, how it…

While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese…

Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the…

Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and…

Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan over a decade ago is poised to drive…

Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under…

[caption id="attachment_92156" align="alignleft" width="227"] Photo: Sofia Linden / Oslo Cancer Cluster[/caption] Oncologist Jon Amund Kyte shares…

Dr Ken-ichiro Hata, representative director and chairperson of Japan's Forum for Innovative Regenerative Medicine (FIRM) outlines the organisation's…

Ameet Mallik, Executive VP and Head of Oncology for the US at Novartis Oncology highlights the company's culture of 'curious, inspired, and unbossed,'…

The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most…

In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare…

Pharmaceutical innovation is racing ahead of the US health system's ability to adjust payment models, but innovative concepts are finally emerging. We…